Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Internal Medicine Neurology Oncology Pediatrics Respiratory Medicine Surgery
Congress Coverage
2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting

ERS International Congress 2023

Catch up on all the top stories and emerging evidence in respiratory medicine with our congress hub page.
ADVANCED SEARCH
Log in
Top
Neurological Sciences

Open Access 18-09-2023 | Parkinson's Disease | Review Article

Diagnostic value of plasma SIRT1 levels and whole-brain gray matter volume in Parkinson’s disease patients with cognitive impairment

Authors: Xiaohuan Li, Dawei Yang, Jianjun Ma, Wei Wei, Jinhua Zheng, Yongyan Fan, Keke Liang, Xiaoxue Shi, Dongsheng Li, Zonghan She, Xuelin Qi, Siyuan Chen

Published in: Neurological Sciences

Login to get access

Abstract

Objective

This study was designed to investigate the diagnostic value of plasma SIRT1 levels and whole-brain gray matter (GM) volume in Parkinson’s disease (PD) patients with cognitive impairment.

Methods

Automated enzymatic analysis was performed to measure plasma SIRT1 levels in 80 healthy controls and 77 PD patients. Motor symptoms and nonmotor symptoms in PD patients were assessed using the corresponding scales. A Siemens MAGNETOM Prisma 3 T MRI scanner was used to acquire images in 35 of 77 PD patients.

Results

Plasma SIRT1 levels in PD patients were lower than those in healthy controls. Plasma SIRT1 levels were negatively correlated with the age, Unified Parkinson’s Disease Rating Scale Part III (UPDRS-III) scores, anxiety, depression, excessive daytime sleepiness (EDS), quality of life, and especially cognitive impairment. Thus, it showed that plasma SIRT1 levels were relevant to visuospatial/executive function, memory, and language. Receiver-operating characteristic (ROC) analysis confirmed that plasma SIRT1 levels had good diagnostic accuracy for PD with anxiety and EDS. Furthermore, plasma SIRT1 levels had a significant positive correlation with GM volume in the whole brain, and ROC analysis confirmed that plasma SIRT1 levels and the total GM volume had good diagnostic accuracy for PD with cognitive impairment.

Conclusions

This study showed that plasma SIRT1 levels were correlated with the nonmotor symptoms of anxiety, depression, EDS, and especially cognitive impairment as well as the total GM volume. Furthermore, the combination of plasma SIRT1 levels and the total GM volume had good diagnostic accuracy for PD with cognitive impairment.
Literature
1.
2.
Schapira AHV, Chaudhuri KR, Jenner P (2017) Non-motor features of Parkinson disease. Nat Rev Neurosci 18(7):435–450 CrossRefPubMed
3.
Pedersen KF, Larsen JP, Tysnes OB, Alves G (2013) Prognosis of mild cognitive impairment in early Parkinson disease: the Norwegian ParkWest study. JAMA Neurol 70(5):580–586 CrossRefPubMed
4.
Broeders M, de Bie RM, Velseboer DC, Speelman JD, Muslimovic D, Schmand B (2013) Evolution of mild cognitive impairment in Parkinson disease. Neurology 81(4):346–352 CrossRefPubMed
5.
Baiano C, Barone P, Trojano L, Santangelo G (2020) Prevalence and clinical aspects of mild cognitive impairment in Parkinson’s disease: a meta-analysis. Mov Disord 35(1):45–54 CrossRefPubMed
6.
Manjula R, Anuja K, Alcain FJ (2020) SIRT1 and SIRT2 activity control in neurodegenerative diseases. Front Pharmacol 11:585821 CrossRefPubMed
7.
Li X, Feng Y, Wang XX, Truong D, Wu YC (2020) The critical role of SIRT1 in Parkinson’s disease: mechanism and therapeutic considerations. Aging Dis 11(6):1608–1622 CrossRefPubMedPubMedCentral
8.
Guo YJ, Dong SY, Cui XX, Feng Y, Liu T, Yin M, Kuo SH, Tan EK, Zhao WJ, Wu YC (2016) Resveratrol alleviates MPTP-induced motor impairments and pathological changes by autophagic degradation of α-synuclein via SIRT1-deacetylated LC3. Mol Nutr Food Res 60(10):2161–2175 CrossRefPubMedPubMedCentral
9.
Ubaid S, Pandey S, Akhtar MS, Rumman M, Singh B, Mahdi AA (2022) SIRT1 mediates neuroprotective and neurorescue effects of camel α-lactalbumin and oleic acid complex on rotenone-induced Parkinson’s disease. ACS Chem Neurosci 13(8):1263–1272 CrossRefPubMed
10.
Feng Y, Liu T, Dong SY, Guo YJ, Jankovic J, Xu H, Wu YC (2015) Rotenone affects p53 transcriptional activity and apoptosis via targeting SIRT1 and H3K9 acetylation in SH-SY5Y cells. J Neurochem 134(4):668–676 CrossRefPubMed
11.
Zhu Y, Zhu X, Zhou Y, Zhang D (2021) Reduced serum SIRT1 levels in patients with Parkinson’s disease: a cross-sectional study in China. Neurol Sci 42(5):1835–1841 CrossRefPubMed
12.
Ashburner J, Friston KJ (2000) Voxel-based morphometry–the methods. Neuroimage 11(6 Pt 1):805–821 CrossRefPubMed
13.
Dalaker T, Zivadinov R, Ramasamy D, Beyer M, Alves G, Bronnick K, Tysnes O, Aarsland D, Larsen J (2011) Ventricular enlargement and mild cognitive impairment in early Parkinson’s disease. Mov Disord: official journal of the Movement Disorder Society 26(2):297–301 CrossRef
14.
Krajcovicova L, Klobusiakova P, Rektorova I (2019) Gray matter changes in Parkinson’s and Alzheimer’s disease and relation to cognition. Curr Neurol Neurosci Rep 19(11):85 CrossRefPubMedPubMedCentral
15.
Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55(3):181–184 CrossRefPubMedPubMedCentral
16.
17.
Rana P, Franco EF, Rao Y, Syed K, Barh D, Azevedo V, Ramos RTJ, Ghosh P (2019) Evaluation of the common molecular basis in Alzheimer's and Parkinson's diseases. Int J Mol Sci 20(15)
18.
Motyl J, Wencel PL, Cieslik M, Strosznajder RP, Strosznajder JB (2018) Alpha-synuclein alters differently gene expression of Sirts, PARPs and other stress response proteins: implications for neurodegenerative disorders. Mol Neurobiol 55(1):727–740 CrossRefPubMed
19.
Maszlag-Torok R, Boros FA, Vecsei L, Klivenyi P (2021) Gene variants and expression changes of SIRT1 and SIRT6 in peripheral blood are associated with Parkinson’s disease. Sci Rep 11(1):10677 CrossRefPubMedPubMedCentral
20.
Chen C, Zhou M, Ge Y, Wang X (2020) SIRT1 and aging related signaling pathways. Mech Ageing Dev 187:111215 CrossRefPubMed
21.
Duncan GW, Khoo TK, Yarnall AJ, O’Brien JT, Coleman SY, Brooks DJ, Barker RA, Burn DJ (2014) Health-related quality of life in early Parkinson’s disease: the impact of nonmotor symptoms. Mov Disord 29(2):195–202 CrossRefPubMed
22.
Kang X, Jiang L, Lan F, Tang YY, Zhang P, Zou W, Chen YJ, Tang XQ (2021) Hydrogen sulfide antagonizes sleep deprivation-induced depression- and anxiety-like behaviors by inhibiting neuroinflammation in a hippocampal Sirt1-dependent manner. Brain Res Bull 177:194–202 CrossRefPubMed
23.
Singh P, Hanson PS, Morris CM (2017) SIRT1 ameliorates oxidative stress induced neural cell death and is down-regulated in Parkinson’s disease. BMC Neurosci 18(1):46 CrossRefPubMedPubMedCentral
24.
Lv J, Jiang S, Yang Z, Hu W, Wang Z, Li T, Yang Y (2018) PGC-1α sparks the fire of neuroprotection against neurodegenerative disorders. Ageing Res Rev 44:8–21 CrossRefPubMed
25.
Uldry M, Yang W, St-Pierre J, Lin J, Seale P, Spiegelman BM (2006) Complementary action of the PGC-1 coactivators in mitochondrial biogenesis and brown fat differentiation. Cell Metab 3(5):333–341 CrossRefPubMed
26.
27.
Liu T, Ma X, Ouyang T, Chen H, Lin J, Liu J, Xiao Y, Yu J, Huang Y (2018) SIRT1 reverses senescence via enhancing autophagy and attenuates oxidative stress-induced apoptosis through promoting p53 degradation. Int J Biol Macromol 117:225–234 CrossRefPubMed
28.
Kumar R, Chaterjee P, Sharma PK, Singh AK, Gupta A, Gill K, Tripathi M, Dey AB, Dey S (2013) Sirtuin1: a promising serum protein marker for early detection of Alzheimer’s disease. PLoS One 8(4):e61560 CrossRefPubMedPubMedCentral
29.
Yan Y, Yang H, Xie Y, Ding Y, Kong D, Yu H (2020) Research progress on Alzheimer’s disease and resveratrol. Neurochem Res 45(5):989–1006 CrossRefPubMed
30.
Sun Z, Zhao S, Suo X, Dou Y (2022) Sirt1 protects against hippocampal atrophy and its induced cognitive impairment in middle-aged mice. BMC Neurosci 23(1):33 CrossRefPubMedPubMedCentral
31.
Cho SH, Chen JA, Sayed F, Ward ME, Gao F, Nguyen TA, Krabbe G, Sohn PD, Lo I, Minami S, Devidze N, Zhou Y, Coppola G, Gan L (2015) SIRT1 deficiency in microglia contributes to cognitive decline in aging and neurodegeneration via epigenetic regulation of IL-1β. J Neurosci 35(2):807–818 CrossRefPubMedPubMedCentral
32.
33.
Ibarretxe-Bilbao N, Junque C, Segura B, Baggio HC, Marti MJ, Valldeoriola F, Bargallo N, Tolosa E (2012) Progression of cortical thinning in early Parkinson’s disease. Mov Disord 27(14):1746–1753 CrossRefPubMed
34.
Boel JA, de Bie RMA, Schmand BA, Dalrymple-Alford JC, Marras C, Adler CH, Goldman JG, Tröster AI, Burn DJ, Litvan I, Geurtsen GJ (2022) Level I PD-MCI using global cognitive tests and the risk for Parkinson’s disease dementia. Mov Disord Clin Pract 9(4):479–483 CrossRefPubMedPubMedCentral
Metadata
Title
Diagnostic value of plasma SIRT1 levels and whole-brain gray matter volume in Parkinson’s disease patients with cognitive impairment
Authors
Xiaohuan Li
Dawei Yang
Jianjun Ma
Wei Wei
Jinhua Zheng
Yongyan Fan
Keke Liang
Xiaoxue Shi
Dongsheng Li
Zonghan She
Xuelin Qi
Siyuan Chen
Publication date
18-09-2023
Publisher
Springer International Publishing
Published in
Neurological Sciences
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI
https://doi.org/10.1007/s10072-023-07071-6